Introduction {#sec1}
============

The secretory prostate organ requires androgen signaling both for development and for proper maintenance of structure and function. Although the adult homeostatic prostate is a predominantly quiescent organ, it harbors a tremendous regenerative capacity that allows it to undergo multiple rounds of androgen-mediated involution and regeneration. Understanding this profound capacity for adult prostate tissue renewal is of great interest for elucidating stem cell biology and may also provide insight into disease.

Unlike the human prostate, which is organized into a single lobe with varying zonal layers, the murine prostate has four distinct lobes surrounding the urethra. The adult prostate contains three epithelial lineages, i.e., basal, luminal, and neuroendocrine cells ([@bib7; @bib10; @bib25]). Luminal cells are columnar androgen-receptor-positive cells that are identified by the cytokeratin markers CK8 and CK18. Basal cells reside adjacent to the luminal cells and express the markers CK5, P63, and CK14. Upon androgen deprivation via castration, 90% of luminal cells undergo apoptosis; however, the luminal cells can be rapidly regenerated following readministration of testosterone, suggesting the existence of stem cells and their important role in prostate regeneration ([@bib3; @bib4; @bib18]). Many hypotheses have been suggested to explain the regenerative process of the adult prostate. Previous work has established that stem cells within the basal compartment divide asymmetrically, generating one stem cell and one committed progenitor cell that differentiates to ultimately yield a luminal or neuroendocrine cell during prostate postnatal development ([@bib12; @bib13]). However, some studies have described multipotency for both luminal ([@bib22]) and basal ([@bib24]) cells following castration-induced involution, while others have supported committed lineage-specified progenitors for luminal and basal cells during adult prostatic regeneration ([@bib3; @bib9]). In addition, an intermediate cell phenotype that is both CK5^+^ and CK18^+^ has been reported ([@bib26]).

During development, prostate expansion is regulated by Wnt signaling ([@bib5; @bib10; @bib21]). The Wnt pathway is highly activated during early stages of prostate development, as well as during prostate regeneration. The Wnt-regulated gene *Lgr5* has been shown to serve as a stem cell marker in several adult tissues, including the ovary, mammary gland, intestinal tract, and hair follicle ([@bib1; @bib6; @bib11; @bib14; @bib15]).

Here, we investigated the possibility that *Lgr5*^+^ cells are a stem cell population within the adult prostate. Our results demonstrate that prostatic *Lgr5*^+^ cells comprise subpopulations within both the luminal and basal compartments. Using in vivo lineage tracing, we discovered that castration-resistant *Lgr5*^+^ cells are long-lived, multipotent progenitors. Moreover, depletion of *Lgr5*^+^ cells revealed that the regenerative potential of the castrated adult prostate requires the *Lgr5*^+^ population of cells. Together, these findings indicate that *Lgr5* identifies an adult stem cell population in the prostate.

Results {#sec2}
=======

*Lgr5* Is Expressed in a Rare Subpopulation of Cells in the Adult Prostate {#sec2.1}
--------------------------------------------------------------------------

By *Lgr5* in situ hybridization on intact adult prostate, we found that *Lgr5* is expressed in a rare subpopulation of cells located in the anterior, dorsal, lateral, and ventral lobes. *Lgr5*^+^ cells were observable in both the basal and luminal compartments of all lobes, as well as in the stromal compartment of the ventral lobes ([Figures 1](#fig1){ref-type="fig"}A and 1B). To further determine the expression pattern of *Lgr5* in the prostate, we pulse labeled *Lgr5*^*CreER2*^*;Rosa26.LSL.tdTomato* (LT) mice with tamoxifen for 24 hr ([Figure 1](#fig1){ref-type="fig"}C). Labeled cells were found in the dorsal, lateral, ventral, and anterior lobes, albeit infrequently, with no observable preference by lobe. The *Lgr5*^+^ (RFP^+^) cells expressed either basal or luminal markers (77.4% of the RFP^+^ cells were luminal cells and 22.6% were basal cells; n = 4 animals, 66 sections, and 97 RFP+ cells; [Figures 1](#fig1){ref-type="fig"}D--1F). Label-positive cells within the stroma were confined to the ventral lobes, consistent with our in situ hybridization data (data not shown). Immunostaining revealed that *Lgr5*^+^ cells did not colocalize with Ki67 ([Figure 1](#fig1){ref-type="fig"}G), providing evidence that these cells were not actively dividing in the adult quiescent prostate. Notably, we did not observe any *Lgr5*^+^ cells coexpressing synaptophysin, a neuroendocrine cell marker (data not shown). *Lgr5*^+^ cells were found in the basal and luminal compartments in all four pairs of lobes (dorsal, lateral, ventral, and anterior) and within the stroma of the ventral lobes of the mouse prostate.

*Lgr5*^+^ Cells Are Castration Resistant {#sec2.2}
----------------------------------------

To determine the androgen dependency of *Lgr5*^+^ cells, we castrated adult LT mice, allowed them to regress for 4 weeks, and then pulse labeled them for 4 consecutive days prior to terminal tissue assessment ([Figure 2](#fig2){ref-type="fig"}A). We identified a castration-resistant subpopulation of *Lgr5*^+^ cells in the fully regressed prostate ([Figures 2](#fig2){ref-type="fig"}B--2E). Sporadic *Lgr5*^+^ cells comprised only 0.068% of total cells in the anterior lobes of the fully regressed mouse prostate ([Figure 2](#fig2){ref-type="fig"}B). Moreover, *Lgr5* mRNA levels did not decrease in 6-week castrated, regressed prostates compared with intact prostates ([Figure 2](#fig2){ref-type="fig"}C). The rare castration-resistant *Lgr5*^+^ cells were in the basal and luminal epithelia in all lobes ([Figures 2](#fig2){ref-type="fig"}D and 2E). However, the labeling efficiency was most prominent in the anterior lobe, and poor in both the ventral and dorsal-lateral lobes. To directly compare the abundance of *Lgr5*^+^ cells in intact and regressed prostates, we utilized *Lgr5*^DTR.EGFP^ mice, which express a knockin GFP fusion protein ([@bib17]). Lin^−^/PI^−^/EpCAM^+^/GFP^+^ cell abundance was 0.023% ± 0.011% in intact prostates and 0.036% ± 0.001% in 6-week castrated prostates ([Figures S1](#app2){ref-type="sec"}A and S1B), suggesting retention of *Lgr5*^+^ castration-resistant cells during regression. The majority (94%) of label-positive *Lgr5*^+^ cells were single cells after the first round of castration and regression, and further quantitation revealed that 75% of these cells were luminal and 25% were basal cells ([Figure S2](#app2){ref-type="sec"}A) expressing the basal cell marker CK5. Taken together, these data demonstrate that a castration-resistant *Lgr5*^+^ population exists in the adult prostate.

Prostatic *Lgr5*^+^ Cells Are Long-Lived Stem Cells {#sec2.3}
---------------------------------------------------

To assess the potential of the castration-resistant population of *Lgr5*^+^ cells to generate progeny during prostate regeneration, we performed in vivo lineage tracing from *Lgr5*^+^ cells. Tamoxifen-mediated labeling in fully regressed prostates and subsequent testosterone-mediated prostate regeneration revealed ribbons (defined as three or more cells) of labeled cells ([Figures 2](#fig2){ref-type="fig"}F and 2G). Quantification of labeled cells demonstrated a 28-fold expansion following the first round of regeneration (0.068% in first-round fully regressed prostates to 1.942% after the first round of regeneration; [Figure 2](#fig2){ref-type="fig"}B). Following a second round of regression ([Figures 2](#fig2){ref-type="fig"}H and 2I), the labeled castration-resistant cells were frequently clustered as doublets, and twice as many labeled cells were identified compared with the first round of regression (round 1: 0.068%; round 2: 0.156%; [Figure 2](#fig2){ref-type="fig"}B). When the cells were allowed to regenerate a second time ([Figures 2](#fig2){ref-type="fig"}J and 2K), a 29-fold expansion of labeled cells between fully regressed and regenerated prostates was observed (0.156% in round 2 regressed to 4.60% in round 2 regenerated prostates; [Figure 2](#fig2){ref-type="fig"}B). These findings show that *Lgr5*^+^ cells and their progeny participate in prostatic expansion during prostate regeneration, and that *Lgr5*^+^ cells not only survived \>19 weeks of regression and regeneration but also maintained a comparable regenerative capacity during the two rounds of regeneration. This indicates that prostatic *Lgr5*^+^ cells are long lived and are capable of self-renewal.

*Lgr5*^+^ Luminal Cells Are Unipotent and Basal Cells Are Bipotent {#sec2.4}
------------------------------------------------------------------

Quantification of the label-positive cells revealed an average of one cell after the first round of regression and two cells after the second round of regression ([Figure 3](#fig3){ref-type="fig"}A). In the regenerated state, the average number of label-positive cells per unit increased to 6 and 10 cells per unit for first and second rounds of regeneration, respectively ([Figure 3](#fig3){ref-type="fig"}A). The labeled units were comprised of basal and/or luminal cells, and the numbers of these cells did not decrease on a per-unit basis during the two rounds of regression and regeneration ([Figures 3](#fig3){ref-type="fig"}B and 3C). In fact, the labeled luminal population doubled in the regressed setting between the first and the second round of regression, suggesting that a subset of *Lgr5*^+^ cell progeny may also be castration resistant ([Figure 3](#fig3){ref-type="fig"}B). Further analysis of the label-positive cells from the first round of regression and regeneration revealed that 70% of the labeled units were of the luminal cell type only ([Figure 3](#fig3){ref-type="fig"}D). In contrast, the average number of basal cells per unit was less than one, and no ribbons (defined as three or more cells) of purely basal cells were observed in either regressed or regenerated prostate ([Figure 3](#fig3){ref-type="fig"}C). These findings indicate that the majority of labeled basal *Lgr5*^*+*^ cells do not give rise exclusively to basal cell progeny during the first round of prostate regeneration, which is consistent with limited loss of basal cells and extensive loss of luminal cells upon androgen deprivation. Overall, the data show that cell expansion from *Lgr5*^+^ cells occurs mostly in the luminal cell compartment during regeneration.

Since we found *Lgr5*^+^ cells within both the basal and luminal compartments upon prostate regression, we sought to elucidate whether they were giving rise to progeny in a uni- or bipotent manner. Label-positive units were found to be composed of luminal cells only, basal cells only, or mixed units containing both luminal and basal cells. Seventy-four percent of the units contained only luminal cells, and the percentage of luminal-only units did not change significantly during regeneration ([Figure 3](#fig3){ref-type="fig"}D), indicating that the majority of luminal *Lgr5*^+^ cells at castrated stages were unipotent. However, the percentage of basal-cell-only units dropped following the first round of regeneration (round 1: 21.2% in the regressed prostate versus 1.6% in the regenerated prostate; [Figure 3](#fig3){ref-type="fig"}E). In contrast, the percentage of mixed units increased following regeneration (round 1: 5.1% in the regressed prostate versus 23% in the regenerated prostate; [Figures 3](#fig3){ref-type="fig"}F and 3G). Notably, in the second round of regression and regeneration, we observed a similar trend, i.e., the percentage of luminal-only units did not change. However, the basal-cell-only units significantly decreased (round 2: 12.6% in the regressed prostate versus 0% in the regenerated prostate) and the mixed units significantly increased (round 2: 17.2% in the regressed prostate versus 36.1% in the regenerated prostate) during the second round of regeneration ([Figures S2](#app2){ref-type="sec"}B--S2D). The presence of mixed units ([Figures 2](#fig2){ref-type="fig"}G, 2K, [S2](#app2){ref-type="sec"}D, and S2E) and the shift from basal-only units to mixed units during each involution-regeneration cycle suggest that most of the *Lgr5*^+^ basal cells were bipotent and giving rise to luminal cells. Moreover, these data suggest that indeed a subset of the *Lgr5*^+^-derived luminal progeny is castration resistant.

Single *Lgr5*^+^ Cells Can Generate Prostatic Cell Lineages {#sec2.5}
-----------------------------------------------------------

To further assess the capacity of *Lgr5*^+^ cells to repopulate the prostate, we used *Lgr5*^*DTR.EGFP*^ mice, which express a knockin GFP fusion protein, to isolate single, viable Lin^−^/EpCAM^+^/GFP^+^ cells from castrated, regressed mouse prostates ([Figure S3](#app2){ref-type="sec"}A). Single fluorescence-activated cell sorting (FACS)-sorted cells were recombined with rat urogenital mesenchyme (UGM) cells and implanted into renal capsules in immunodeficient male mice ([Figure 4](#fig4){ref-type="fig"}A). Seventy-five percent of *Lgr5*^+^ single-cell implantations generated large and translucent grafts after 3 months ([Figures 4](#fig4){ref-type="fig"}B and 4C). Histological analysis of the grafts showed that they had a branching morphology and expressed luminal cell, basal cell, and neuroendocrine markers ([Figures 4](#fig4){ref-type="fig"}D, 4E, and [S3](#app2){ref-type="sec"}B), indicating that single *Lgr5*^+^ cells can generate prostatic structures containing all three epithelial cell lineages. We conclude that *Lgr5* labels a subset of stem cells in the regressed prostate with the capacity to generate multilineage prostatic structures from a single cell in renal capsule transplantation experiments.

*Lgr5*^+^ Cells Are Necessary for Prostate Regeneration {#sec2.6}
-------------------------------------------------------

We next wanted to ascertain whether the castration-resistant *Lgr5*^+^ cells were required for prostate regeneration. To this end, we took advantage of the *Lgr5*-targeted knockin animal, which expresses human diphtheria toxin receptor (DTR) from the endogenous *Lgr5* locus (*Lgr5*^*DTR.EGFP*^). Through systemic administration of diphtheria toxin (DT), we selectively culled *Lgr5*^+^ cells. Animals with fully regressed prostates were then challenged to regenerate in the absence of *Lgr5*^+^ cells by concurrent administration of DT and testosterone for 9 days ([Figures 5](#fig5){ref-type="fig"}A and [S4](#app2){ref-type="sec"}A). Compared with wild-type littermates, the DT-treated *Lgr5*^*DTR.EGFP*^ animals had significantly smaller prostates ([Figure 5](#fig5){ref-type="fig"}B). To confirm that the heterozygous state of *Lgr5* in *Lgr5*^*DTR.EGFP*^ mice did not influence prostate regeneration, we treated *Lgr5*^*DTR.EGFP*^ mice with vehicle (PBS) concurrently with testosterone, and in contrast to the DT-treated *Lgr5*^*DTR.EGFP*^ mice, the PBS-treated *Lgr5*^*DTR.EGFP*^ mice showed normal prostate regeneration ([Figures 5](#fig5){ref-type="fig"}B and [S4](#app2){ref-type="sec"}B). A closer examination of the epithelial composition showed that the ratio of CK18^+^ luminal cells to CK5^+^ basal cells in the anterior lobe was significantly lower in the DT-treated cohort (DT-treated: CK18/CK5, 0.49; PBS-treated: CK18/CK5, 1.82; [Figures 5](#fig5){ref-type="fig"}C and [S4](#app2){ref-type="sec"}C). This suggests that *Lgr5*^+^ cell depletion leads to impaired luminal cell expansion and the prostate remains in an early stage of regeneration in which basal cells are enriched. Interestingly, BrdU incorporation revealed that the percentage of BrdU^+^ cells was ∼5-fold higher in the DT-treated cohort, again reminiscent of an early stage of regeneration (DT, 8.6%; PBS, 1.5%; [Figures 6](#fig6){ref-type="fig"}A--6C). These data suggest that depletion of *Lgr5*^*+*^ cells leads to altered luminal cell differentiation and expansion, and impaired prostate regeneration. Gene expression analysis further revealed that cluster of differentiation 31 (*CD31*), vascular endothelial growth factor receptor 1 (*VEGFR1*), and Wnt pathway target genes (e.g., *β-catenin* and *Axin 2*) were significantly elevated in *Lgr5*-depleted prostates ([Figure 6](#fig6){ref-type="fig"}D). This expression profile is reminiscent of an earlier stage (days 1--3) of prostate regeneration ([@bib20; @bib21]), pointing to a delayed regeneration response upon *Lgr5*^+^ cell depletion in the prostate. Taken together, these findings demonstrate that *Lgr5*^+^ cells are required for prostate regeneration, and depletion of *Lgr5*^+^ cells leads to impaired luminal cell expansion and prostate regeneration.

Discussion {#sec3}
==========

Experimental evidence has shown that *Lgr5* is a marker of stem cells in the skin, small intestine, ovary, and mammary gland. Herein, we report the finding of a subpopulation of *Lgr5*-expressing stem cells in the mouse prostate that are long-lived and can generate both luminal and basal cells both in situ during prostate regeneration and within renal capsule implantation studies using single *Lgr5*^+^ cells. *Lgr5*^+^ cells, particularly the basal *Lgr5*^+^ cells, meet the two criteria of stem cells (longevity and multipotency) and thus are identified as stem cells in the prostate. Our in situ hybridization and pulse-label studies indicate that *Lgr5*^+^ cells are a rare cell population in the adult prostate. In contrast to the basal expression pattern of *Lgr5*^+^ cells in adult mammary glands ([@bib15]), prostatic *Lgr5*^+^ cells are mostly located in the luminal compartment. Although most luminal cells are androgen dependent and undergo apoptosis following androgen depletion by castration, castration-resistant luminal *Lgr5*^+^ cells were observed. The *Lgr5*^+^ cells and their progeny survived two rounds of regression and regeneration, and maintained a similar regeneration capacity over time. Our in situ regeneration data demonstrated that basal *Lgr5*^+^ cells were bipotent, but the vast majority of the luminal *Lgr5*^+^ cells were unipotent. However, we cannot exclude the possibility that a small portion of luminal *Lgr5*^+^ cells can also be bipotent in situ. Previous work has established that stem cells within the basal compartment divide asymmetrically, generating one stem cell and one committed progenitor cell that differentiates to ultimately yield a luminal or neuroendocrine cell during prostate postnatal development ([@bib12; @bib13]). However, there is some controversy about the cellular hierarchy that governs adult prostate regeneration following castration-induced involution. Some studies have described multipotency for both luminal ([@bib22]) and basal ([@bib24]) cells, and others have supported committed lineage-specified progenitors for both luminal and basal cells during adult prostatic regeneration ([@bib3; @bib9]). All of these studies used similar genetic lineage-tracing methodologies. Our data suggest that by tracing from the rare *Lgr5*^*+*^ cells obtained from castrated, regressed prostates during regeneration, we obtained evidence of basal cell bipotency in situ, and observed unipotent division of luminal cells only. Therefore, our work seems to agree with the most recent work by [@bib24]), in which basal cells demonstrated both symmetric and asymmetric divisions leading to distinct cell fates, and luminal cells only exhibited symmetric divisions during adult prostate regeneration.

Renal capsule implantation of *Lgr5*^+^ cells further supported the high repopulation capacity of single *Lgr5*^+^ cells within the regressed prostate. A limiting-dilution analysis indicated that every prostatic *Lgr5*^+^ cell could be a stem cell in regressed prostates, meaning that both luminal and basal *Lgr5*^+^ cells in regressed prostates could obtain a bipotent capacity in the transplantation setting. Importantly, cell types have been shown to acquire a facultative plasticity in single-cell ex vivo and renal-capsule assays that is not readily observable in vivo ([@bib3; @bib23; @bib25]). This is consistent with recent work that identified multipotent basal and luminal cells in a human organoid culture system ([@bib7]). It seems that prostatic *Lgr5*^+^ cells are capable of bipotentiality depending on the environmental cues or assay conditions, i.e., these cells can generate luminal progeny in response to a demand for luminal epithelial cells in androgen manipulation studies in situ, or give rise to both luminal and basal progeny to repopulate the prostate structure from single cells in transplantation studies.

Moreover, in this study we demonstrate that *Lgr5*^+^ cells are required for prostate regeneration after castration and subsequent androgen substitution, as depletion of *Lgr5*^+^ cells led to the generation of significantly smaller prostates. Considering the low frequency of *Lgr5*^+^ cells in the prostate and the profound impact of *Lgr5*^+^ depletion on prostate regeneration, we speculated that *Lgr5*^+^ cells could give rise to other progenitor cells to mediate the regeneration process. Indeed, we observed an increase in labeled cells during two rounds of regression and regeneration. The average unit size in the second-round regressed prostates was two cells, compared with one in the first-round regressed prostate. The additional labeled cell is most likely derived from the single *Lgr5*^+^ cell from the first round of regression. This cell is also castration resistant and its expansion rate is similar to that of the original *Lgr5*^+^ cell, suggesting that *Lgr5*^+^ stem cells in the regressed prostate are self-renewing and the newly generated stem cell also takes part in the regeneration process. More studies will be required to elucidate the networking and the symmetry of divisions of stem cells and progenitor cells in the prostate.

With regard to human prostate cancer, tumor cells are largely characterized by luminal phenotypes, and loss of basal cells is the hallmark of prostate adenocarcinoma. However, there is evidence for both basal and luminal cell lineages initiating the disease. Initially, prostate tumors respond to androgen deprivation therapy well, but eventually tumors progress in the absence of androgen, suggesting the possible presence of resistant cells that are responsible for repopulating the tumor. *Lgr5*^+^ cells have been shown to be a cell of origin for intestinal tumors ([@bib2]). Although *LGR5* is expressed in both human prostate tissues and prostate tumors ([Figure S5](#app2){ref-type="sec"}), it is unclear what role LGR5^+^ cells play in prostate cancer initiation or maintenance. Interestingly, the majority of castration-resistant *Lgr5*^*+*^ cells are of luminal origin, and it was recently demonstrated that luminal cells are the preferred cell of origin for preclinical prostate murine tumor models ([@bib25]). If castration-resistant *Lgr5*^*+*^ cells can serve as the cell of origin for castration-resistant prostate cancer (CRPC), then selectively targeting these *Lgr5*^*+*^ cells during androgen-deprivation treatment should be considered as a therapeutic strategy to prevent CRPC. It will be important to continue to explore the role of *Lgr5*^+^ cells in prostate cancer biology to assess their potential for tumor initiation, especially given that our studies demonstrate that *Lgr5*^+^ cells are castration-resistant, long-lived stem cells that are required for complete prostate regeneration following castration.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

E18 pregnant rats and athymic nu/nu male mice at 8 weeks of age were purchased from Harlan Sprague Dawley. *Lgr5*^*DTR.EGFP*^ and *Lgr5*^*CreER*^ mice were generated as previously described ([@bib17]). *Lgr5*^*CreER*^ mice were interbred with the Rosa26.LSL.tdTomato mouse line to generate *Lgr5*^*CreER*^*;Rosa26.LSL.tdTomato* (LT) mice. The animals were dosed and monitored according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Genentech.

Antibodies {#sec4.2}
----------

The following antibodies were used: CK5 (1:1,000, PRB-160P; Covance), P63 (1:600, clone 4A4; Santa Cruz Biotechnology), CK8 (1:1,000, MMS-162P; Covance), CK18 (1:500, ab82254; Abcam), Ki67 (1:200, RM-9106; Thermo Scientific), anti-BrdU (1:1,000, \#347580; Becton Dickinson), and Alexa Fluor 488 donkey anti-rabbit IgG (H+L, 1:500, A-21206; Life Technologies).

Castration, Tamoxifen Labeling, and Prostate Regeneration {#sec4.3}
---------------------------------------------------------

Surgery was conducted using aseptic procedures. Following preparation of the surgical site, an incision was made in the scrotum. Then an incision was made in the tunica of the first testicle. The testis, vas deferens, and attached testicular fat pad were pulled out of the incision. The blood vessels supplying the testis were cauterized. The testis, vas deferens, and fatty tissue were severed just below the site of cauterization. The tunica on the contralateral side was similarly penetrated and the procedure was repeated. The scrotum incision was closed with a 4-0 absorbable Vicryl suture. Four weeks after castration, LT mice were administered tamoxifen at 5 mg/20 g, or corn oil by oral gavage daily for four consecutive days. A 12.5 mg/pellet/mouse testosterone pellet was implanted 2 weeks after the last dose of tamoxifen.

Renal Capsule Grafting and Testosterone Pellet Implantation {#sec4.4}
-----------------------------------------------------------

Animals were anesthetized using ketamine/xylazine. The back of the skin (dorsal midline over the lumbar) was prepped with povidone iodine and 70% ethanol. The back skin was lifted with a pair of blunt forceps and a lumbar incision was made with a pair of scissors, creating an incision approximately 1 inch long. The animal was placed on its side and a small incision was made in the body wall just along the long axis of the kidney. A pair of fine forceps (\#5) was used to gently pinch and lift the capsule from the parenchyma of the kidney so that a 2--4 mm incision was made in the capsule with fine spring-loaded scissors. Grafts were transferred to the surface of the kidney using forceps. The body wall was closed with a 4-0 Vicryl suture. A testosterone pellet (12.5 mg/pellet, one pellet/mouse) was placed between the body wall and skin. After grafting, the edges of the back skin were aligned and closed with a 4-0 absorbable Vicryl suture.

UGM Preparation {#sec4.5}
---------------

UGM cells were dissociated from embryonic day 18 (E18) embryos from pregnant Sprague Dawley rats as described previously ([@bib8; @bib10; @bib18]). Briefly, UGM cells from E18 embryos were dissociated with 1 mg/ml of collagenase/dispase (Roche) in DMEM plus 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml of penicillin and streptomycin for 1 hr at 37°C. UGM cells were cultured in DMEM with 10% FBS, 2 mM glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 ng/ml selenium, 1 nM testosterone (Innovative Research of America), 100 U/ml penicillin, and 100 mg/ml streptomycin. UGM cells were passaged with trypsin twice and used within 7 days after tissue dissociation.

Flow Cytometry {#sec4.6}
--------------

Five to eight prostates were harvested and pooled together for one FACS sorting or analysis experiment. Prostate cells were dissociated as described previously ([@bib8; @bib16; @bib22]). Cells were non-lineage depleted using a mouse lineage cell depletion kit (130-090-858; Miltenyi Biotec), stained with propidium iodide (PI), and analyzed on an LSR-II flow cytometer (Becton Dickinson). Single cells were sorted into individual wells of U-bottom 96-well plates containing 20 μl of collagen type I by an LSR-II flow cytometer (Becton Dickinson), and confirmed with an inverted Olympus Ix81 microscope.

DT Treatment and BrdU Labeling In Vivo {#sec4.7}
--------------------------------------

Adult male mice were castrated and 4 weeks later were implanted with a testosterone pellet (as described above) administered concurrently with DT (catalog \#322326; EMD) at 50 ng/g, intraperitoneally (i.p.). The DT treatment was administered every other day, for a total of four times. BrdU (550891; BD PharMingen) was administered at 200 μl/mouse, 10 mg/ml, i.p., 16 hr before the mice were euthanized. The mice were euthanized and prostates were harvested on day 9 after the first DT treatment.

Immunohistochemistry and Image Acquisitions {#sec4.8}
-------------------------------------------

Prostates were fixed with 4% paraformaldehyde for 2--3 hr on ice, followed by 30% sucrose overnight at 4**°**C, embedded in OCT, and sectioned at 5--6 μm. Sections were blocked with 10% normal goat or donkey serum for 1 hr at room temperature, incubated with primary antibodies over night at 4**°**C, followed by secondary antibody incubation for 30 min at room temperature. Serial sections of each mouse prostate were observed and imaged on either a Zeiss Axioplan 2 imaging microscope with an ORCA-ER digital camera (Hamamatsu), or on Olympus BX61 upright microscope. Or, whole slide images were acquired by the Ariol SL-50 automated slide scanning platform (Leica Microsystems) at 100× final magnification using standard fluorescence filters. Scanned slides were analyzed in the MATLAB software package (version R2012b; The MathWorks). Individual cell nuclei were segmented using a radial symmetry based method applied to the DAPI channel ([@bib19]) and then scored for the presence of CK5, CK18 signal above a global intensity threshold in the area immediately surrounding each nucleus.

RNA Extraction {#sec4.9}
--------------

Tumor samples were placed into RNALater (Ambion) at 4°C for ∼24 hr. Then, 30 mg of tissue was excised from the total tissue collected and total RNA was extracted with the QIAGEN AllPrep Kit (QIAGEN) following the manufacturer's protocol. RNA quantity was determined using Nanodrop (Thermo Scientific) and the quality was assessed by Agilent 2100 Bioanalyzer (Agilent Technologies) according to the manufacturers' protocol.

RNA Reverse Transcription {#sec4.10}
-------------------------

The 20 μl reverse transcription reaction contained 10 μl of 10 ng/μ of total RNA, 2 μl of 10× RT buffer, 0.8 μl of 100 mM dNTPs, 2 μl of 10× RT Random Hexamer Primers; 1 μl of RNase inhibitor (20 U/μl), 1 μl of Multiscribe Reverse Transcriptase (50 U/μl), and 3.2 μl of H~2~O. All reagents were purchased from Applied Biosystems (part number 4374966). The reaction mixture was mixed with the RNA and incubated as follows; 25°C for 10 min, 37°C for 120 min and then 85°C for 5 min.

Preamplification of cDNA {#sec4.11}
------------------------

A total of 96 TaqMan assays (Life Technologies) were pooled at a final concentration of 0.2× for each assay. Pre-PCR amplification reaction was done at 5 μl containing 2.5 μl TaqMan PreAmp Master Mix (2×, part number 4391128), 1.25 μl of 96-pooled TaqMan assay mix (0.2×) and 1.25 μl of cDNA from the reverse transcription reaction described above. The pre-amplification PCR was incubated as follows: one cycle at 95°C for 10 min, and 14 cycles at 95°C for 15 s and then at 60°C for 4 min. After preamplification PCR, the product was diluted 1:5 with TE buffer (Ambion, part number 9849) and stored at −80°C until needed.

RNA Expression Analysis Using a 96.96 Dynamic Array {#sec4.12}
---------------------------------------------------

Reverse transcription and preamplification were performed as described above. Quantitative PCR was carried out using the 96.96 dynamic array platform (Fluidigm) following the manufacturer's protocol. Specifically, a 6 μl sample mixture was prepared for each sample containing 3 μl of TaqMan Universal Master Mix (part number 4304437), 0.3 μl of Sample Loading Reagent (part number 85000746) and 2.7 μl of diluted, preamplified cDNA. A 6 μl assay mixture was prepared with 3 μl of each TaqMan assay and 3 μl of Assay Loading Reagent (part number 85000736). An Integrated Fluidic Circuit (IFC) controller was used to prime the 96.96 Dynamic Array IFC chip with control line fluid, and 5 μl of both the sample and assay mixes were loaded into the appropriate inlets. After loading, the chip was placed in the BioMark Instrument for PCR at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The data were analyzed with Real-Time PCR Analysis Software (Fluidigm).

Quantitative Real-Time RT-PCR {#sec4.13}
-----------------------------

Quantitative real-time RT-PCR was performed on a 7900HT thermal cycler (Applied Biosystems) with the following primers and probes: *Lgr5* (cat\# Mm00438890_m1, Applied Biosystems); *Ctnnb1* (cat\# Mm00483039_m1, Applied Biosystems); *CD31* (cat\# Mm01242584_m1, Applied Biosystems); VEGFR1 (cat\# Mm00438980_m1, Applied Biosystems); Axin2: forward primer, TGGCTTTGACTACGCCCAC; reverse primer, GGGAGCTGAAGCGCTGG, probe, CCCAACGCGCCCTCTTTGATCTG; RPL19: forward 5′-AGA AGG TGA CCT GGA TGA GAA-3′, reverse 5′- TGA TAC ATA TGG CGG TCA ATC T-3′, probe 5′- CTT CTC AGG AGA TAC CGG GAA TCC AAG-3′.

Quantification and Statistics {#sec4.14}
-----------------------------

Three to 11 mice were used for each time point of analysis. tdTomato^+^ cells and the ratio of CK18^+^/CK5^+^ cells were analyzed using the MATLAB software package (version R2012b; The MathWorks) following whole-slide imaging as described above. The numbers of luminal and basal cells per tdTomato^+^ unit were counted based on CK5-Alexa 488^+^, tdTomato fluorescence, and DAPI^+^ on Adobe Photoshop CS6. BrdU^+^ cells were counted manually using 20× images. The t test, F test, and chi-square test were used for statistical analysis. Three or more animals were analyzed for each experiment.
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![*Lgr5* Is Expressed in the Intact Adult Mouse Prostate\
(A and B) In situ hybridization of *Lgr5* in adult mice (8--10 weeks old; n = 4) luminal (arrows), basal (black arrowhead), and stroma (red arrowhead) cells in ventral (A) and anterior (B) lobes.\
(C) Experimental design.\
(D--G) Immunofluorescent images of *Lgr5*^+^ cells pulse labeled with tamoxifen for 24 hr in *Lgr5*^*CreER*^*;Rosa26.LSL.tdTomato* (LT) mice, showing RFP positivity and CK5 (D), P63 (E), CK8 (F), and Ki67 (G) in anterior (D and G) and dorsolateral (E and F) lobes.](gr1){#fig1}

![Lineage Tracing of *Lgr5*^+^ Cells in Two Rounds of Prostate Regression and Regeneration\
(A) Experimental design of lineage-tracing studies.\
(B) Percentage of label-positive cells per total cells at different stages of the two rounds of regression and regeneration: round 1 regressed, n = 3 mice, number of cells counted (cn) = 18,159; round 1 regenerated, n = 11 mice, cn = 31,375; round 2 regressed, n = 7 mice, cn = 11,756; round 2 regenerated, n = 5 mice, cn = 18,070.\
(C) Quantification of relative *Lgr5* expression in intact and castrated prostates; n = 4 mice per group.\
(D and E) Immunofluorescent images of *Lgr5*^+^ (RFP^+^) cells (red) and CK5 (green) in anterior lobes of round 1 (R1) regressed prostates. Labeled cells were identified in the luminal (D) and basal (E) compartments.\
(F and G) Immunofluorescent images of *Lgr5*^+^ (RFP^+^) progeny (red) and CK5 (green) in round 1 regenerated prostates. Labeled cells were in the luminal compartment only (F) or in both the luminal and basal compartments, arrows (G).\
(H and I) Immunofluorescent images of *Lgr5*^+^ (RFP^+^) progeny (red) and CK5 (green) in anterior lobes of round 2 (R2) regressed prostates. Labeled cells were observed in both the basal (H) and luminal (I) compartments.\
(J and K) Immunofluorescent images of *Lgr5*^+^ (RFP^+^) progeny (red) and CK5 (green) in anterior lobes of round 2 regenerated prostates. Labeled cells were exclusively in the luminal compartment (J) or in both the luminal and basal compartments, arrows (K).\
All values are presented as mean and SEM. testo, testosterone; n, number of mice; cn, number of cells counted. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001. See also [Figure S1](#app2){ref-type="sec"}.](gr2){#fig2}

![Unit Analysis of *Lgr5*^+^ Progeny Reveals Uni- and Bipotent Properties\
(A) Quantitation of labeled cells at the indicated stages of regression and regeneration per unit.\
(B and C) Quantitation of unit composition as the number of labeled luminal (B) or basal (C) cells per unit.\
(D and E) Unit characterization as the percentage of luminal-only (D), basal-only (E), or mixed (F) units.\
(G) Pie graph representation of unit content at the indicated stages of prostate regression and regeneration, showing the number of animals per stage (n) and total number of units counted (uc): R1 regressed, n = 3, uc = 33; R1 regenerated, n = 11, uc = 150; R2 regressed, n = 7, uc = 84; R2 regenerated, n = 5, uc = 121. Units counted per mouse = 9--43.\
All values are represented as mean and SEM; n.s., not significant; ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#app2){ref-type="sec"}.](gr3){#fig3}

![Single *Lgr5*^+^ Cells from Regressed Prostates Harbor Stem Cell Potential\
(A) Experimental design.\
(B and C) Six weeks after surgical castration, single Lin^−^/PI^−^/EpCAM^+^/GFP^+^ cells were isolated and implanted into the renal capsule of athymic nu/nu male mice together with rat UGM cells for 3 months, and the prostate regeneration capacity of UGM-only control (B) and the single Lin^−^/PI^−^/EpCAM^+^/GFP^+^ cell implant (C) was assessed. Successful grafts demonstrating both CK5 and CK8 immunofluorescence positivity were 0/18 transplanting UGM-only and 3/4 transplanting Lin^−^/PI^−^/EpCAM^+^/GFP^+^ cells; ^∗∗∗∗^p \< 0.0001.\
(D and E) Successful engraftment and expansion was confirmed by immunofluorescence staining for CK5 (red), CK8 (green) (D), and synaptophysin (Syn, in green) (E).\
See also [Figure S3](#app2){ref-type="sec"}.](gr4){#fig4}

![Depletion of *Lgr5*^+^ Cells Impairs Prostate Regeneration\
(A) Experimental design summary. Six weeks after surgical castration, testosterone pellet implantation was performed concurrently with diphtheria toxin (DT) treatment (DT treatment every other day).\
(B) Quantification of prostate wet weights from *Lgr5*^DTR.EGFP^ mice fully regressed and administered PBS + testo or DT + testo.\
(C) Quantification of the ratio of CK18/CK5 in anterior lobes of prostates (n = 3 mice per group). Two coronal prostatic sections per mouse were analyzed by whole-slide scan, using the imaging protocol described in [Experimental Procedures](#sec4){ref-type="sec"}.\
(D and E) Immunofluorescence of CK5 (red) and CK18 (green) in anterior lobes from prostates treated with PBS (D) or DT (E). Right: enlargements of designated areas showing only single channels. ^∗∗^p \< 0.01, ^∗∗∗∗^p ≤ 0.0001.\
See also [Figure S4](#app2){ref-type="sec"}.](gr5){#fig5}

![Delayed Regenerative Profiles following Depletion of *Lgr5*^+^ Cells\
(A and B) Immunofluorescence of BrdU in the anterior lobes of prostate sections from *Lgr5*^*DTR.EGFP*^ mice administered either PBS (A) or DT (B). The insets are enlarged images of the boxed areas.\
(C) Quantification of BrdU^+^ cells as a percentage of total epithelial cells in the anterior lobes of prostates: DT, 8.6%, cn = 11,242, n = 3 mice; PBS, 1.5%, cn = 9145, n = 3 mice; p = 0.005.\
(D) Transcriptional analysis of prostate tissue following *Lgr5*^+^ cell depletion; n = 4 animals per group.\
All values are represented as mean and SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01.](gr6){#fig6}
